LncRNA MIR31HG targets HIF1A and P21 to facilitate head and neck cancer cell proliferation and tumorigenesis by promoting cell-cycle progression

Wang, Ru; Ma, Zhiyong; Li, Feng; Yang, Yifan; Tan, Chen; Shi, Qian; Lian, Meng; He, Shizhi; Ma, Hongzhi; Fang, Jugao

doi:10.1186/s12943-018-0916-8

Cited by 121 publications

(99 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Functionally, dysregulation of lncRNAs is associated with the abnormality of biological processes . To determine the involvement of HCG11 in the tumorigenesis of glioma, we conducted the gain or loss‐of functional assays in two glioma cells.…”

Section: Discussionmentioning

confidence: 99%

“…Functionally, dysregulation of lncRNAs is associated with the abnormality of biological processes. [36][37][38] To determine the involvement of HCG11 in the tumorigenesis of glioma, we conducted the gain or loss-of functional assays in two glioma cells. According to the experimental results, we concluded that HCG11 negatively regulated cell growth in glioma.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Long non‐coding RNA HCG11 suppresses the growth of glioma by cooperating with the miR‐4425/MTA3 axis

Zhang

Cao

Kou

et al. 2019

The Journal of Gene Medicine

View full text Add to dashboard Cite

Background Glioma is a type of malignant tumor that occurs in the central nervous system of adults. Long non‐coding RNAs (lncRNAs) that potentially participate in the initiation and progression of glioma have been widely reported. As a now‐found lncRNA, HLA complex group 11 (HCG11) has not yet been studied in glioma. The present study aimed to determine the role of HCG11 in the tumorigenesis of glioma. Methods A quantitative real‐time polymerase chain reaction assay was performed to examine the expression pattern of HCG11 in 84 glioma tissues and cell lines. The overall survival rate of glioma patients with a high or low level of HCG11 or metastasis‐associated 1 family member 3 (MTA3) was analyzed by Kaplan–Meier analysis. The effect of HCG11 on glioma cell growth was determined by in vitro and in vivo experiments. MicroRNAs (miRNAs) that potentially interact with HCG11 were searched and determined by bioinformatics analysis and a luciferase reporter assay. Similarly, the target of miRNA‐4425 was identified. Finally, rescue assays were conducted to determine the bio‐function of the competing endogenous RNA pathway. Results HCG11 was downregulated in 84 pairs of glioma tissues and cell lines. Moreover, a low level of HCG11 indicted the lower overall survival rate of glioma patients. Regarding the mechanism, HCG11 was abundant in the cytoplasm of glioma cells and interacted with miR‐4425 to release the expression of MTA3. miR‐4425 and MTA3 participated in HCG11‐mediated glioma growth. Conclusions LncRNA HCG11 suppresses the growth of glioma by cooperating with the miR‐4425/MTA3 axis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Long non‐coding RNA HCG11 suppresses the growth of glioma by cooperating with the miR‐4425/MTA3 axis

Zhang

Cao

Kou

et al. 2019

The Journal of Gene Medicine

View full text Add to dashboard Cite

show abstract

“…LncRNA MIR31HG, locating at human chromosome 9p21.3 [40] with transcription regulated by methylation of the promoter region [27], was found aberrantly expressed in several types of cancers. Specifically, MIR31HG was found elevated expressed in breast cancer [13], cervical cancer [28], chordoma [16], osteosarcoma [15], lung cancer [2,23,41], OSCC [4], PDAC [7], VSCC [29] and LSCC [36,42,43]. Nevertheless, the expression levels of MIR31HG was reported down-regulated in triple-negative breast cancer (TNBC) cell lines of basal subtype [27], bladder cancer [26], gastric cancer [25], CRC [32,33], and HCC [6].…”

Section: Discussionmentioning

confidence: 99%

“…According to the screening criteria, seventeen articles comprising 2573 patients were included in our study [1,2,4,6,15,17,19,23,25,26,[28][29][30][31][32][33]36]. All the included studies were related to lncRNA MIR31HG in cancer and comprised clinical data.…”

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

The predictive value of lncRNA MIR31HG expression on clinical outcomes in patients with solid malignant tumors

Ren

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Background: Emerging studies have explored the prognostic value of MIR31HG in cancers, but its role remains elusive. Herein, we aimed to summarize the prognostic potential of MIR31HG in this study. Methods: Several databases were searched for literature retrieval on Dec 5, 2019. Overall and subgroup analyses were conducted to measure the relationship between MIR31HG expression and clinical outcomes. Moreover, GEPIA was applied for validation of prognostic value of MIR31HG in tumor patients in TCGA dataset. Results: Overall, seventeen studies with 2573 patients were enrolled. Compared to counterparts, those patients with high MIR31HG expression tended to have shorter RFS. Notably, MIR31HG overexpression predicted unfavorable OS in lung cancer. By contrast, gastrointestinal cancer patients with elevated MIR31HG expression predicted better OS and disease-free survival. Additionally, MIR31HG overexpression was significantly associated with worse clinicopathological features including advanced tumor stage and LNM in lung cancer, but favorable clinical characteristics in gastrointestinal cancer. Moreover, the positive association between MIR31HG and OS in lung cancer was further confirmed in TCGA dataset. Conclusion: Overexpression of MIR31HG suggested remarkable association with poor prognosis in terms of OS, tumor stage, and LNM in lung cancer, but favorable prognosis in gastrointestinal cancer. Therefore, MIR31HG may serve as a promising prognostic biomarker in multiple cancers.

show abstract

“…Flow cytometry was performed according to the manufacture's protocol [21]. HN4 and Cal27 cells transfected with lncMX1-215 or vector were harvested 48 h after transfection.…”

Section: Flow Cytometrymentioning

confidence: 99%

A novel IFNα-induced long noncoding RNA negatively regulates immunosuppression by interrupting H3K27 acetylation in head and neck squamous cell carcinoma

Chang

Yang

et al. 2020

Mol Cancer

View full text Add to dashboard Cite

Background: Interferon alpha (IFNα) is a well-established regulator of immunosuppression in head and neck squamous cell carcinoma (HNSCC), while the role of long noncoding RNAs (lncRNAs) in immunosuppression remains largely unknown.Methods: Differentially expressed lncRNAs were screened under IFNα stimulation using lncRNA sequencing. The role and mechanism of lncRNA in immunosuppression were investigated in HNSCC in vitro and in vivo. Results:We identified a novel IFNα-induced upregulated lncRNA, lncMX1-215, in HNSCC. LncMX1-215 was primarily located in the cell nucleus. Ectopic expression of lncMX1-215 markedly inhibited expression of the IFNα-induced, immunosuppression-related molecules programmed cell death 1 ligand 1 (PD-L1) and galectin-9, and vice versa. Subsequently, histone deacetylase (HDAC) inhibitors promoted the expression of PD-L1 and galectin-9. Binding sites for H3K27 acetylation were found on PD-L1 and galectin-9 promoters. Mechanistically, we found that lncMX1-215 directly interacted with GCN5, a known H3K27 acetylase, to interrupt its binding to H3K27 acetylation. Clinically, negative correlations between lncMX1-215 and PD-L1 and galectin-9 expression were observed. Finally, overexpression of lncMX1-215 suppressed HNSCC proliferation and metastasis capacity in vitro and in vivo. Conclusions: Our results suggest that lncMX1-215 negatively regulates immunosuppression by interrupting GCN5/ H3K27ac binding in HNSCC, thus providing novel insights into immune checkpoint blockade treatment.

show abstract

LncRNA MIR31HG targets HIF1A and P21 to facilitate head and neck cancer cell proliferation and tumorigenesis by promoting cell-cycle progression

Cited by 121 publications

References 10 publications

Long non‐coding RNA HCG11 suppresses the growth of glioma by cooperating with the miR‐4425/MTA3 axis

Long non‐coding RNA HCG11 suppresses the growth of glioma by cooperating with the miR‐4425/MTA3 axis

The predictive value of lncRNA MIR31HG expression on clinical outcomes in patients with solid malignant tumors

A novel IFNα-induced long noncoding RNA negatively regulates immunosuppression by interrupting H3K27 acetylation in head and neck squamous cell carcinoma

Contact Info

Product

Resources

About